Original Article

Prognostic value of platelet indices in patients with acute pulmonary thromboembolism

Samad Ghaffari1, Nashmil Parvizian1, Leili Pouraskari1,2, Ahmad Separham1, Reza Hajizadeh1, Nader D Nader2*, Elnaz Javanshir1, Nariman Sepehrvand1, Arezou Tajlil1, Babak Nasiri1

1Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2Department of Anesthesiology, State University of New York at Buffalo, Buffalo, NY, USA
3Department of Cardiology, Urmia University of Medical Sciences, Urmia, Iran
4Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada

Abstract

Introduction: Given the role of platelets in thrombus formation, markers of platelet activation may be able to predict outcomes in patients with acute pulmonary thromboembolism (PTE).

Methods: In a prospective cohort study, 492 patients with acute PTE were enrolled. Patients were evaluated for platelet indices including mean platelet volume (MPV), platelet distribution width (PDW), and platelet-lymphocyte-ratio (PLR), as well as for the simplified Pulmonary Embolism Severity Index (PESI) risk score. The primary endpoint was in-hospital all-cause mortality. Major adverse cardiopulmonary events (MACPE, composite of mortality, thrombolysis, mechanical ventilation and surgical embolectomy during index hospitalization) and all-cause death during follow-up were secondary endpoints.

Results: MPV, PDW and PLR were 9.9±1.0 fl, 13.5±6.1%, and 14.7±14.5, respectively, in the total cohort. Whilst MPV was higher in those with adverse events (10.1±1.0 fl vs 9.9±1.0 fl; P=0.019), PDW and PLR were not different between two groups. MPV with a cut-off point of 9.85 fl had a sensitivity of 81% and a specificity of 50% in predicting in-hospital mortality, but it had lower performance in predicting MACPE (Area under the curve: AUC 0.58; 95%CI 0.52-0.63) or long-term mortality (AUC 0.54; 95% CI 0.47-0.61). The AUC for all these three markers were lower than the AUC calculated for the simplified PESI score (0.80; 0.71-0.88).

Conclusion: Platelet indices had only fair-to-good predictive performance in predicting in-hospital all-cause death. Established PTE risk scoring models such as simplified PESI outperform these indices in predicting adverse outcomes.

Introduction

Pulmonary thromboembolism (PTE) is a major cause of cardiovascular mortality worldwide with a case fatality rate of 15% within the early post-diagnosis phase. It incurs 7-10 billion dollars annually to the healthcare system only in the United States. Risk stratification and prognostication is of great importance in patients who present to emergency department with acute PTE, and follows two main purposes: Identifying low-risk patients that can be treated as an outpatient and finding high-risk cases that may benefit from second-line therapies such as thrombolysis or surgical embolectomy. Beside risk stratification tools such as Pulmonary Embolism Severity Index (PESI), readily available blood parameters have been recently proposed to be predictors of clinical outcome in venous thromboembolism.

Given the established role of platelets in thrombogenesis, platelet activation is considered as an expected phenomenon in PTE. Mean platelet volume (MPV) and platelet distribution width (PDW) are markers of platelet production and activation. Higher MPV (i.e. larger platelets) is shown to be associated with the presence of more granules, higher levels of thromboxane A2, rapid aggregation with collagen, and more glycoprotein Ib and IIb/IIa receptors.6,7

Furthermore, the Leukocytes’ physiologic response to stress usually presents with an increase in the sympathetic activity and cortisol levels as well as an increase in the number of neutrophils which is associated with a decrease in the number of lymphocytes. This leads to the extravasation of neutrophils into the affected area. Platelet-lymphocyte ratio (PLR), as a surrogate marker of inflammation, may be used to explore the link between thrombosis and inflammation in PTE, which is mediated by the production of reactive oxygen species and higher levels of myeloperoxidase enzyme, the consequent oxidative stress, and the release of pro-inflammatory cytokines such as IL-6 and TNF-α.

In this study, we measured the levels of MPV, PLR and PDW in a cohort of patients who were diagnosed with...
acute PTE in emergency department to investigate the predictive performance of these biomarkers in predicting adverse outcomes in this patient population.

Materials and Methods
In a single-center prospective cohort study, 492 patients with a confirmed diagnosis of acute pulmonary embolism were enrolled at Madani Heart Hospital in Tabriz, Iran, between March 2011 and March 2015.

Study population
Patients with an age older than 18 years presenting to hospital with chest pain or dyspnea with a primary diagnosis of acute PTE were included. The diagnosis of acute PTE has been made using multidetector computed tomography (CT) angiography. CT angiography result was considered diagnostic for PTE in the presence of intraluminal filling defect or arterial cut-off. In patients who were contraindicated to undergo CT angiography because of a history of contrast allergy, patients with severe renal dysfunction (estimated glomerular filtration rates <30 mL/min) or pregnant women, the diagnosis of acute PTE was established using ventilation/perfusion (V/Q) scintigraphy and high probability scans were considered as diagnostic. Patients were excluded if they were admitted >24 hours after the symptom onset, if they had a prior history of PTE or an underlying disease limiting the life expectancy to less than one month (e.g. major trauma or high-grade cancer).

Demographic information, comorbidities, admission vital signs, echocardiographic findings, admission laboratory data before receiving treatment as well as main treatment protocol and survival status during hospitalization of included patients were recorded in prepared questionnaires by a trained physician.

We calculated simplified PESI score using variables of age >80 years, pulse rate ≥110 beats/minute, systolic blood pressure <100 mm Hg, history of cancer, chronic cardiopulmonary disease, and arterial oxygen saturation <90%.

Laboratory measurements
Venous blood samples on admission were obtained and collected in citrated tubes containing EDTA potassium salt additive as an anticoagulant. Blood samples were transferred to and analyzed by hospital laboratory within one hour. Total white blood cell, neutrophil, lymphocyte and platelet counts, hemoglobin, PDW and MPV were recorded for each patient. Biochemical analysis was performed to measure blood urea nitrogen (BUN), creatinine and blood glucose. For performing differential complete blood count analyses, an automated Coulter CBC H1 counter, which was calibrated on a daily basis was used. PLR was calculated as the platelet count divided by the absolute lymphocyte count per one cubic millimeter (mm³). NLR was calculated as the absolute neutrophil count divided by the absolute lymphocyte count per one cubic millimeter (mm³).

Follow up
Patients were followed during the index hospital stay and regularly afterwards in the outpatient clinics for one year.

Outcomes
The primary endpoint of interest in this study was in-hospital all-cause mortality. Major adverse cardiopulmonary events (MACPE), defined as a composite of the all-cause mortality and the need for thrombolysis, mechanical ventilation and surgical embolectomy during the index hospitalization and all-cause death during follow-up were secondary endpoints.

Statistical analysis
Mean and standard deviation (SD) were presented for continuous variables and frequency (%) for categorical variables. For comparison between groups with and without clinical events, the independent t test, Mann-Whitney U rank sum test and the Pearson χ² test, were used.

Receiver operating characteristics (ROC) curve was used to determine the area under the curve (AUC) and to identify the optimal cut-off point of MPV, PDW, PLR and the simplified PESI score in predicting different clinical outcomes including in-hospital death, in-hospital MACPE, and follow-up death. Pearson correlation test was done between MPV and total platelet counts, cardiac troponin levels, and systolic pulmonary arterial pressure as well as between platelet indices and the PESI risk score. All data analyses were performed using SPSS (Version 21.0; IBM SPSS Corporation, Chicago, IL) and P values <0.05 were considered statistically significant.

Results
In this prospective cohort study, 492 patients with confirmed acute PTE were enrolled. The mean age was 62.1 ± 17.1 years and 48% of cases (236 patients) were male. Patient demographics, clinical presentations, and baseline laboratory and imaging findings are summarized in Tables 1-3.

Outcomes
Median length of stay (LOS) at hospital was 9 days (1st and 3rd quartiles 7, 12), and in-hospital death occurred in 42 (8.5%) patients. Ninety-seven patients (19.7%) received fibrinolytic therapy during the index hospitalization. Thirty-five (7.1%) and 23 (4.7%) patients underwent mechanical ventilation and embolectomy, respectively. In total, 151 patients (30.7%) experienced the composite endpoint of all-cause death, thrombolysis, mechanical ventilation and surgical embolectomy during the index hospitalization.

Patients were followed up for a median period of 13
months (interquartile range: 3-23 months). All-cause mortality occurred in 107 patients (21.7%) during the follow-up period.

**Platelet indices**

Total platelet counts were lower in patients who suffered a major adverse event in hospital compared to others (183.6 ± 76.9 vs 214.3 ± 86.6 cells/nL; *P* < 0.001). MPV was 9.9 ± 1.0 fl in the total cohort, and it was higher in those with MACPE as compared to their counterparts (10.1 ± 1.0 vs 9.9 ± 1.0; *P* = 0.019).

PDW was 13.5 ± 6.1% in the total cohort and it was not different between groups with and without MACPE (13.6 ± 2.7% vs 13.5 ± 7.0%; *P* > 0.05). Similarly, PLR was 14.7 ± 14.5 in this study population and was not different between patients who had in-hospital MACPE compared to others (15.7 ± 16.5 vs 14.2 ± 13.5; *P* > 0.05).

Pearson correlation test revealed that MPV was inversely correlated with the total platelet count (*r*(490) = - 0.29; *P* < 0.001) (Figure 1). There was no correlation between MPV and cardiac troponin levels (*r*(401) = 0.05; *P* = 0.3). Also there was no correlation between MPV and cardiac troponin levels.

Table 1. Patient characteristics in the study population and in groups with and without major adverse cardiopulmonary events (MACPE)

|                      | Total (n=492) | With MACPE (n=151) | Without MACPE (n=341) | P value |
|----------------------|--------------|--------------------|-----------------------|---------|
| Age, year            | 62.1 ± 17.2  | 58.9 ± 18.1        | 63.5 ± 16.6           | 0.006   |
| Male sex, n(%)       | 236 (48.0)   | 77 (51.0)          | 159 (46.6)            | 0.371   |
| Seasonal distribution|              |                    |                       |         |
| Spring               | 122 (24.8)   | 33 (21.9)          | 89 (26.2)             | 0.397   |
| Summer               | 142 (28.9)   | 46 (30.5)          | 96 (28.2)             |         |
| Fall                 | 111 (22.6)   | 40 (26.5)          | 71 (20.9)             |         |
| Winter               | 116 (23.6)   | 32 (21.2)          | 84 (24.7)             |         |
| Comorbidities        |              |                    |                       |         |
| Hypertension         | 206 (42.0)   | 55 (36.7)          | 151 (44.3)            | 0.115   |
| Diabetes mellitus    | 72 (14.6)    | 24 (18.8)          | 48 (14.9)             | 0.309   |
| Congestive heart failure | 39 (7.9) | 8 (5.3)          | 31 (9.1)              | 0.151   |
| Hyperlipidemia on statins | 50 (21.6) | 15 (21.4)          | 35 (21.6)             | 0.976   |
| COPD                 | 43 (8.7)     | 9 (6.0)            | 34 (10.0)             | 0.146   |
| Past/current smoker  | 63 (14.0)    | 22 (17.2)          | 41 (12.7)             | 0.215   |
| Concurrent DVT       | 16 (5.2)     | 5 (5.7)            | 11 (5.0)              | 0.781   |
| Active Cancer        | 34 (6.9)     | 10 (6.6)           | 24 (7.0)              | 0.867   |
| Recent history of immobility | 98 (19.9) | 31 (20.5)          | 67 (19.6)             | 0.821   |
| Recent long distance travelling | 8 (1.6) | 3 (2.0)            | 5 (1.5)               | 0.706   |
| Oral contraceptives  | 20 (4.1)     | 4 (2.6)            | 16 (4.7)              | 0.290   |

COPD: chronic obstructive pulmonary disease.

Table 2. Clinical presentation and imaging findings in patients with and without major adverse cardiopulmonary events (MACPE)

|                  | Total (n=492) | With MACPE (n=151) | Without MACPE (n=341) | P value |
|------------------|--------------|--------------------|-----------------------|---------|
| Hypothermia      | 131 (34.9)   | 38 (34.9)          | 93 (35.0)             | 0.985   |
| Dyspnea          | 401 (81.5)   | 122 (80.8)         | 279 (81.8)            | 0.787   |
| Tachypnea > 20 bpm | 245 (57.0)  | 77 (60.2)          | 168 (55.6)            | 0.386   |
| Pleuritic chest pain | 68 (13.8)  | 12 (7.9)           | 56 (16.4)             | 0.012   |
| Subternal chest pain | 81 (16.5)  | 20 (13.2)          | 61 (17.9)             | 0.200   |
| Syncope          | 55 (11.2)    | 31 (20.5)          | 24 (7.0)              | <0.001  |
| Tachycardia > 100 bpm | 229 (47.6) | 88 (60.3)          | 141 (42.1)            | <0.001  |
| RV enlargement   | 310 (64.2)   | 128 (85.3)         | 182 (54.7)            | <0.001  |
| RV diameter on CT (mm) | 4.62 ± 0.94 | 4.46 ± 0.81       | 4.66 ± 0.98           | 0.471   |
| RV dysfunction   | 288 (59.6)   | 123 (82.0)         | 165 (49.5)            | <0.001  |
| Right/Left ventricular ratio | 0.79 ± 0.19 | 0.75 ± 0.14       | 0.81 ± 0.20           | 0.300   |
| Systolic pulmonary pressure | 50.6 ± 21.3 | 55.2 ± 20.0       | 48.0 ± 21.7           | 0.003   |
| Clot on echocardiogram | 33 (6.9)  | 27 (18.1)          | 6 (1.8)               | <0.001  |
| Presence of saddle embolus | 51 (12.5) | 32 (25.8)          | 19 (6.7)              | <0.001  |
| Segmental pulmonary emboli | 119 (23.9) | 19 (15.4)          | 100 (36.0)            | <0.001  |

RV: right ventricle.
Platelet indices in acute pulmonary thromboembolism

J Cardiovasc Thorac Res, 2020, 12(1), 56-62

systolic pulmonary arterial pressure \( r(343)=0.03, P=0.4 \) in this study population. Unlike MPV \( r(10)=0.10, P=0.14 \) and PDW \( r(0.05, P=0.51) \), PLR was correlated with the risk level determined by the simplified PESI score \( r=0.25, P=0.001 \).

**Prognostic performance**

Figure 2 depicts the ROC curves of the predictive performance of different platelet parameters in predicting in-hospital mortality. The predictive performance of these indices in predicting various patient outcomes such as in-hospital mortality, in-hospital MACPE, and death during follow-up period are summarized in Table 4. MPV with a cut-off point of 9.85 fl has a sensitivity and specificity of 81% and 50%, respectively in predicting in-hospital mortality in patients with acute PTE, but it had lower performance in predicting composite endpoints (i.e. MACPE AUC 0.58; 95% CI 0.52-0.63) or long-term mortality (AUC 0.54; 95% CI 0.47-0.61). PDW with the cut-point of 13.6% and PLR with the cut-point of 12.8, respectively had an AUC of 0.66 (95% CI 0.52, 0.80) and 0.61 (95% CI 0.50, 0.72) in predicting in-hospital mortality. In general, platelet indices in our study showed poorer performance when compared to the well-established risk score of the simplified PESI (Table 4). In Table 5, clinical outcomes were compared between patients with different levels of MPV, PDW and PLR.

We also performed a survival analysis to compare the all-cause mortality in the follow-up period between patients with different levels of MPV (Figure 3) and the Kaplan-Meier curve showed no difference between these two groups in terms of intermediate- to long-term mortality (log-rank test; \( P=0.8 \)).

| Laboratory findings | Total (n=492) | With MACPE (n=151) | Without MACPE (n=341) | P value |
|---------------------|--------------|-------------------|-----------------------|---------|
| Hemoglobin (g/dL)   | 12.8 ± 2.4   | 12.8 ± 2.5        | 12.7 ± 2.3            | 0.607   |
| White blood cell count (103 cells/mL) | 11.3 ± 9.3 | 13.9 ± 15.5 | 10.2 ± 3.9 | 0.005 |
| Neutrophil lymphocyte ratio | 6.2 ± 6.2 | 6.8 ± 6.2 | 5.8 ± 6.2 | 0.206 |
| Platelets (10^12 counts/mL) | 205.0 ± 84.9 | 183.6 ± 76.9 | 214.3 ± 86.6 | <0.001 |
| Mean platelet volume (femtoliter) | 9.9 ± 1.0 | 10.1 ± 1.0 | 9.9 ± 1.0 | 0.019 |
| Platelet distribution width | 13.5 ± 6.1 | 13.6 ± 2.7 | 13.5 ± 7.0 | 0.914 |
| Platelet lymphocyte ratio (PLR) | 14.7 ± 14.5 | 13.7 ± 16.5 | 14.2 ± 13.5 | 0.338 |
| Cardiac troponin I (ng/L) | 0.45 ± 1.12 | 0.68 ± 1.40 | 0.35 ± 0.96 | 0.019 |
| Serum d-dimer (µg/mL) | 2.1 ± 2.0 | 2.4 ± 2.1 | 1.9 ± 1.9 | 0.178 |
| Arterial partial pressure of O2 (mm Hg) | 62.1 ± 28.2 | 64.4 ± 34.2 | 60.9 ± 24.6 | 0.337 |
| Arterial partial pressure of CO2 (mm Hg) | 37.7 ± 11.1 | 38.0 ± 11.7 | 37.5 ± 10.8 | 0.708 |
| Blood glucose | 138.7 ± 77.5 | 151.5 ± 93.5 | 133.6 ± 69.7 | 0.064 |
| Serum creatinine (mg/dL) | 1.3 ± 1.0 | 1.2 ± 0.5 | 1.3 ± 1.2 | 0.714 |
| Alkaline phosphatase (IU/L) | 262.0 ± 168.4 | 223.8 ± 104.9 | 277.7 ± 186.8 | 0.055 |
| Alanine aminotransferase (IU/L) | 66.4 ± 86.3 | 73.2 ± 76.1 | 63.4 ± 90.6 | 0.562 |
| Aspartate aminotransferase (IU/L) | 55.4 ± 75.7 | 55.0 ± 54.7 | 55.5 ± 83.5 | 0.974 |
| Serum Total Cholesterol (mg/dL) | 167.5 ± 46.1 | 161.3 ± 38.6 | 170.0 ± 48.7 | 0.095 |
| Low density lipoprotein (mg/dL) | 104.0 ± 37.2 | 96.9 ± 29.8 | 107.0 ± 39.6 | 0.034 |
| Very low density lipoprotein (mg/dL) | 31.6 ± 25.5 | 28.4 ± 10.4 | 33.2 ± 30.4 | 0.598 |

**Table 3. Laboratory findings in patients with and without major adverse cardiopulmonary events (MACPE)**

**Figure 1. Correlation between MPV and total platelet count in this population.**

**Figure 2. Receiver operating curve for evaluating sensitivity and specificity of platelet indices in predicting in-hospital death.**

J Cardiovasc Thorac Res, 2020, 12(1), 56-62 | 59
Table 4. The predictive performance of mean platelet volume (MPV), platelet distribution width (PDW), and platelet-lymphocyte ratio (PLR), in prognosticating different clinical outcomes

|                      | AUC (95% CI) | Cut-point | Sensitivity | Specificity |
|----------------------|-------------|-----------|-------------|-------------|
| **MPV**              |             |           |             |             |
| In-hospital death    | 0.67 (0.58-0.76) | 9.85 fl  | 81.0%       | 49.6%       |
| MACPE                | 0.58 (0.52-0.63) | 9.85 fl  | 65.6%       | 52.5%       |
| Follow up death      | 0.54 (0.47-0.61) | 10.0 fl  | 51.4%       | 57.1%       |
| **PDW**              |             |           |             |             |
| In-hospital death    | 0.66 (0.52-0.80) | 13.60    | 66.7%       | 65.2%       |
| MACPE                | 0.57 (0.51-0.64) | 12.35    | 73.1%       | 46.7%       |
| Follow up death      | 0.50 (0.42-0.59) | 13.65    | 45.0%       | 66.4%       |
| **PLR**              |             |           |             |             |
| In-hospital death    | 0.61 (0.50-0.72) | 12.8     | 61.0%       | 63.2%       |
| MACPE                | 0.47 (0.42-0.54) | 9.8      | 52.1%       | 46.0%       |
| Follow up death      | 0.65 (0.58-0.72) | 11.4     | 63.1%       | 63.5%       |
| **Simplified PESI**  |             |           |             |             |
| In-hospital death    | 0.80 (0.71-0.88) | 1.5      | 77.3%       | 70.4%       |
| MACPE                | 0.69 (0.62-0.77) | 0.5      | 90.5%       | 42.1%       |
| Follow up death      | 0.76 (0.66-0.86) | 1.5      | 60.4%       | 80.5%       |

Table 5. Clinical outcomes in groups with different levels of mean platelet volume (MPV), platelet distribution width (PDW), and platelet-lymphocyte ratio (PLR)

|                      | MPV≤9.85 fl (n=231) | MPV>9.85 fl (n=261) | p   | PDW≤13.6 fl (n=241) | PDW>13.6 fl (n=139) | p   | PLR≤12.8 fl (n=286) | PLR>12.8 fl (n=182) | p   |
|----------------------|----------------------|----------------------|-----|---------------------|---------------------|-----|---------------------|---------------------|-----|
| SBP <90 mm Hg        | 13 (5.7)             | 26 (10.2)            | 0.18| 18 (7.6)            | 11 (8.3)            | 0.76| 16 (5.8)            | 20 (11.1)           | <0.01|
| Cardiac arrest       | 2 (0.9)              | 2 (0.8)              | 1.00| 2 (0.8)             | 2 (1.4)             | 0.62| 2 (0.7)             | 2 (1.1)             | 0.64 |
| Vasopressor treatment| 3 (2.1)              | 18 (11.2)            | <0.01| 8 (5.3)             | 10 (11.8)           | 0.07| 15 (8.1)            | (5.9)               | 0.49 |
| Oxygen saturation (%) | 84.9 ±12.8           | 86.3 ±11.8           | 0.33| 86.0 ±13.2          | 85.9 ±12.3          | 0.94| 86.0 ±12.5          | 85.4 ±12.3          | 0.66 |
| Blood urea nitrogen  | 21.5 ±11.9           | 26.3 ±17.8           | 0.04| 22.1 ±13.3          | 26.3 ±18.6          | 0.16| 23.3 ±14.4          | 25.1 ±17.3          | 0.47 |
| Fibrinolytic therapy | 38 (16.5)            | 59 (22.6)            | 0.08| 45 (18.7)           | 21 (15.1)           | 0.37| 58 (20.3)           | 34 (18.7)           | 0.67 |
| Mechanical ventilation| 5 (2.2)              | 30 (11.5)            | <0.01| 12 (5.0)            | 15 (10.8)           | 0.03| 20 (7.0)            | 15 (8.2)            | 0.61 |
| Surgical embolectomy | 7 (3.0)              | 16 (6.1)             | 0.10| 9 (3.7)             | 9 (6.5)             | 0.22| 14 (4.9)            | 7 (3.8)             | 0.59 |
| Hospital LOS (days)  | 9.5 ±4.9             | 11.0 ±9.2            | 0.02| 10.3 ± 4.4          | 11.5 ±10.6          | 0.24| 10.8 ±8.3           | 9.8 ± 6.5           | 0.18 |
| In-hospital death    | 8 (3.5)              | 34 (13.0)            | <0.01| 7 (2.9)             | 14 (10.1)           | <0.01| 16 (5.6)            | 25 (13.7)           | <0.01|
| MACPE                | 52 (22.5)            | 99 (37.5)            | <0.01| 63 (26.1)           | 45 (32.4)           | 0.19| 87 (30.4)           | 57 (31.3)           | 0.83 |

Discussion

In this study, we explored the prognostic value of platelet indices in predicting adverse outcomes in patients with acute PTE. Several key findings are noteworthy. MPV was higher in patients who had adverse events during their index hospital stay as compared to those who did not. All three indices had fair to good predictive performance in predicting in-hospital all-cause death. They performed poorer in predicting long-term mortality or in predicting a composite endpoint including death and other non-fatal adverse events. Despite having fair performance, established PTE risk scoring models such as PESI outperform these indices in predicting adverse outcomes.

Larger platelets have more glycoprotein IIb and glycoprotein IIa receptors, and they release higher levels of thromboxane A2, platelet factor 4 and β-thromboglobulin, hence they are more metabolically and enzymatically reactive and have higher thrombotic potentials. Platelets are involved in the pathogenesis of various diseases and elevated MPV has been associated with higher risk of adverse events in several disease conditions, such as acute coronary syndrome, stroke, and venous thromboembolism setting. It has been reported to be a risk indicator for predicting the possibility of PTE in patients with unprovoked DVT.

Considering the presence of hypercoagulable state in venous thromboembolism and acute PTE and purported
Platelets indices in acute pulmonary thromboembolism

pro-thrombotic properties of platelets with higher MPV, it is expected to see a correlation between high MPV and clinical outcomes in this specific disease. Several studies have explored and demonstrated its diagnostic value in diagnosing acute PTE among the suspected patients. A study by Günay et al showed that MPV and PDW can be useful in determining the severity of pulmonary vascular bed obstruction in PTE (i.e. massive vs submassive). Several studies suggested its correlation with right ventricular (RV) dimensions and the severity of RV dysfunction. Nevertheless, these studies were not consistent so far and some studies failed to find a correlation between MPV and disease severity.

In this study, the simplified PESI outperformed the platelet indices in prognosticating patients with acute PTE. Akgülü et al in a study showed that the predictive performance of extensively-studied risk scores such as the simplified PESI can be improved by addition of factors such as MPV.

Like several previous studies, MPV correlated inversely with the total platelet count. This can be attributed to the consumption of platelets for thrombus formation and a compensatory production of larger platelets from megakaryocytes in the bone marrow.

Previous studies have showed a relationship between PLR and a high risk of in-hospital mortality in patients with acute PTE and found it to be correlated with established risk scores (e.g. simplified PESI). Similarly, in this study, PLR was correlated with the simplified PESI, whilst the other two indices lacked such correlation. However, the PLR levels were not different between patient with and without adverse events and it only had a fair predictive performance in predicting in-hospital mortality.

It is important to delineate the pathophysiologic mechanisms with which the activated platelet is linked to acute PTE itself and moreover to the adverse events in patients with acute PTE. A vicious cycle between the platelet activation and pulmonary vascular bed obstruction is the most legitimate explanation. The mechanisms that contribute include sympathetic activation resulted from hypoxemia which in turn leads to platelet activation and the release of angiotensin II, pulmonary vasoconstriction due to the release of thromboxane A2 from platelets, hypercoagulability secondary to an increase in the plasma levels of platelet factor-4 and β-thromboglobulin and increase in platelet-fibrinogen binding resulted from the overexpression of adhesion molecules such as P-selectin, glycoprotein Ib and glycoprotein IIb/IIIa in platelets.

There are several potential limitations to this study. This study was a single-center observational study and it was subject to biases that are innate to observational studies. Our study included patients of a single center and one snap shot of blood samples has been utilized at the time of admission. Serial measurement and study of temporal changes were not possible in our study setting. There may be also racial and ethnical differences in normal ranges in a given population.

Conclusion
In conclusion, platelet indices had only fair-to-good predictive performance in predicting in-hospital all-cause death. Despite having fair prognostication, established PTE risk scoring models such as simplified PESI outperform these indices in predicting adverse outcomes.

Competing interests
The authors declare that there are not conflicts of interest.

Ethical approval
The study was approved by the Ethics committee of Tabriz University of Medical Sciences and informed consent was obtained from all participants prior to study enrollment.

References
1. Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med 2008; 359: 2804-13. doi: 10.1056/NEJMcp0804570
2. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res 2016; 137: 3–10. doi: 10.1016/j.thromres.2015.11.033
3. Jimenez D, Aujesky D, Moores L, Gomez V, Lobo JL, Uresandi F, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170: 1383–9. doi: 10.1001/archinternmed.2010.199
4. Ostovian MA, Ghaffari S, Pourakbari L, Dehghani P, Hajizadeh R, Nadiri M, et al. Modification of Simplified Pulmonary Embolism Severity Index and its Prognostic Value in Patients with Acute Pulmonary Embolism. Heart Lung Circ 2016; 25: 184-90. doi: 10.1016/j.hlc.2015.08.008
5. Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa
and size are increased in acute myocardial infarction. *Eur J Clin Invest* 1994; 24: 69-72.
6. Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thrombomodulin B2 production and megakaryocyte nuclear DNA concentration. *Thromb Res* 1983; 32: 443-60.
7. George JN. Platelets. *Lancet* 2000; 355: 1531-9. doi: 10.1016/s0140-6736(00)02175-9
8. Muhl D, Furedi R, Cristofari J, Ghosh S, Bogar L, Borsiczki B, et al. Evaluation of oxidative stress in the thrombolysis of pulmonary embolism. *J Thromb Thrombolysis* 2006; 22: 221-8. doi: 10.1007/s11239-006-9035-2
9. Ovechkin AV, Lominadze D, Sedoris KC, Robinson TW, Tyagi SC, Roberts AM. Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions. *Arch Physiol Biochem* 2007; 113: 1-12. doi: 10.1080/13813450601118976
10. Marchena Yglesias PJ, Nieto Rodriguez JA, Serrano Martinez S, Belinchon Moya O, Cortes Carmona A, Diaz de Tuesta A, et al. [Acute-phase reactants and markers of inflammation in venous thromboembolic disease: correlation with clinical and evolution parameters]. *An Med Interna* 2006; 23: 105-10.
11. Balta S, Demirkol S, Kucuk U. The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice. *Hemodial Int* 2013; 17: 668-9. doi: 10.1111/hdi.12058
12. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. *Blood Coagul Fibrinolysis* 1996; 7: 157-61.
13. Ghaffari S, Pourafkari L, Javadzadegan H, Masoumi N, Jafarabadi MA, Nader ND. Mean platelet volume is a predictor of ST resolution following thrombolysis in acute ST elevation myocardial infarction. *Thromb Res* 2015; 136: 101-6. doi: 10.1016/j.thromres.2015.05.003
14. Greisenegger S, Endler K, Hsieh K, Tentschert S, Mannhalter C, Lalouczech W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? *Stroke* 2004; 35: 1688-91. doi: 10.1161/01.STR.0000130512.81212.a2
15. Chung T, Connor D, Joseph J, Emmett L, Mansberg R, Peters M, et al. Platelet activation in acute pulmonary embolism. *J Thromb Haemost* 2007; 5: 918-24. doi: 10.1111/j.1538-7836.2007.02461.x
16. Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromso Study, Tromso, Norway. *J Thromb Haemost* 2010; 8: 157-62. doi: 10.1111/j.1538-7836.2009.03498.x
17. Icli A, Aksoy F, Turker Y, Uysal BA, Alpay MF, Dogan A, et al. Relationship Between Mean Platelet Volume and Pulmonary Embolism in Patients With Deep Vein Thrombosis. *Heart Lung Circ* 2015; 24: 1081-6. doi: 10.1016/j.hlc.2015.04.170
18. Talay F, Ocak T, Alcelik A, Erkuran K, Akkaya A, Duran A, et al. A new diagnostic marker for acute pulmonary embolism in emergency department: mean platelet volume. *Afr Health Sci* 2014; 14: 94-9. doi: 10.4314/ahs.v14i15.15
19. Kostrubiec M, Labyk A, Pedowska-Wloszek J, Hrynkiewicz-Szymanska A, Pacho S, Jankowski K, et al. Mean platelet volume predicts early death in acute pulmonary embolism. *Heart* 2010; 96: 460-5. doi: 10.1136/hrt.2009.180489
20. Gunay E, Sarinc Ulasli S, Kacar E, Halici B, Unlu E, Tunay K, et al. Can platelet indices predict obstruction level of pulmonary vascular bed in patients with acute pulmonary embolism? *Clin Respir J* 2014; 8: 33-40. doi: 10.1111/crj.12031
21. Varol E, Icli A, Uysal BA, Ozaydin M. Platelet indices in patients with acute pulmonary embolism. *Scand J Clin Lab Invest* 2011; 71: 163-7. doi: 10.3109/00365513.2010.547596
22. Yardan T, Meric M, Kati C, Celenk Y, Atici AG. Mean platelet volume and mean platelet volume/platelet count ratio in risk stratification of pulmonary embolism. *Medicina (Kaunas)* 2016; 52: 110-5. doi: 10.1016/j.medici.2016.03.001
23. Ates H, Ates I, Kundi H, Yilmaz FM. Diagnostic validity of hematologic parameters in evaluation of massive pulmonary embolism. *J Clin Lab Anal* 2017; 31. doi: 10.1002/jcla.22072
24. Akgullu C, Omurlu IK, Eryilmaz U, Avcil M, Dagtekin E, Akdeniz M, et al. Predictors of early death in patients with acute pulmonary embolism. *Am J Emerg Med* 2015; 33: 214-21. doi: 10.1016/j.ajem.2014.11.022
25. Gasparyan AY, Ayyazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? *Curr Pharm Des* 2011; 17: 47-58.
26. Kundi H, Balun A, Cicekcioglu H, Cetin M, Kiziltunc E, Cetin ZG, et al. The relation between platelet-to-lymphocyte ratio and Pulmonary Embolism Severity Index in acute pulmonary embolism. *Heart Lung* 2015; 44: 340-3. doi: 10.1016/j.hrtlng.2015.04.007
27. Ozdemir O, Soyru M, Alyan O, Geyik B, Demir AD, Aras D, et al. Association between mean platelet volume and autonomic nervous system functions: Increased mean platelet volume reflects sympathetic overactivity. *Exp Clin Cardiol* 2004; 9: 243-7.
28. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. *Blood Coagul Fibrinolysis* 2000; 11: 61-9.
29. Chung I, Lip GY. Platelets and heart failure. *Eur Heart J* 2006; 27: 2623-31. doi: 10.1093/eurheartj/ehl305
30. Inami N, Nomura S, Kikuchi H, Kajiura T, Yamada K, Nakamori H, et al. P-selectin and platelet-derived microparticles associated with monocyte activation markers in patients with pulmonary embolism. *Clin Appl Thromb Hemost* 2003; 9: 309-16.